All told, 7% of patients treated with SpringWorks' therapy had a complete response to treatment, and 95% of side effects liked to the drug were mild (grade 1 or 2), most commonly diarrhoea, rash ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial ...

J.P.  Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...

A new biotech spun out of Pfizer is to develop four drugs for rare and serious diseases. SpringWorks is the brainchild of Lara Sullivan, a former Pfizer R&D strategy executive who gained Pfizer's ...

When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had ...

SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis ...